Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03980561 · ClinicalTrials.gov registry record · Phase 2
UH3 Varenicline for Cannabis Use Disorder
A Phase 2 study of Cannabis Use Disorder, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Phase 2
- Development phase
- 174
- Enrollment target
- 2
- Study locations
NCT03980561 is a Phase 2 study of Cannabis Use Disorder that has completed, run by Medical University of South Carolina. The registered enrollment target is 174 participants, above the 104-participant average among 34 other Cannabis Use Disorder trials with a reported enrollment target (67% higher). The trial reports 2 study locations across 1 state.
The verdict
NCT03980561, a Phase 2 study of Cannabis Use Disorder, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 174 participants
- Enrollment target
- 2
- Study locations
Study Summary
Marijuana is the most commonly used illicit drug. There is high demand for effective interventions for cannabis use disorder, yet few specific treatments for have been developed. This study will evaluate the efficacy of varenicline for reducing marijuana use in people who use marijuana frequently.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Varenicline
Study Locations (2)
South Carolina
- Medical University of South Carolina - Charleston
- Behavioral Health Services of Pickens County - Pickens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2020-01-31 |
| Est. Completion | 2023-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03980561
The ClinicalTrials.gov registry entry for NCT03980561 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 174 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 104-participant average among 34 other Cannabis Use Disorder trials with a reported enrollment target (67% higher). The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cannabis Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03980561 reports 2 study locations spanning 1 distinct geographic area - top geographies include South Carolina.
Frequently Asked Questions
What is clinical trial NCT03980561 about?
NCT03980561 is a clinical study titled "UH3 Varenicline for Cannabis Use Disorder". Marijuana is the most commonly used illicit drug. There is high demand for effective interventions for cannabis use disorder, yet few specific treatments for have been developed. This study will evaluate the efficacy of varenicline for reducing marijuana use in people who use marijuana frequently.
What is the current status of trial NCT03980561?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 174 participants. The study started on 2020-01-31. Estimated completion is 2023-12-01.
What conditions does trial NCT03980561 study?
This clinical trial studies the following conditions: Cannabis Use Disorder.
What interventions are being tested in trial NCT03980561?
The interventions under investigation include: Placebo (DRUG), Varenicline (DRUG).
Who is sponsoring clinical trial NCT03980561?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03980561 being conducted?
This trial has 2 study locations across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cannabis Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Longitudinal Outpatient Treatment for Cannabis Use Disorder
RECRUITING · Phase 2
-
A Study of Cannabidiol in Young Adult Cannabis Users
RECRUITING · Phase 2
-
Effects of THC on Alcohol Consumption and Neural Correlates of Reward
RECRUITING · Phase 2
-
Cannabidiol and Cannabis Concentrate Users
RECRUITING · Phase 2
-
A Teleheath tDCS Approach to Decrease Cannabis Use
COMPLETED · Phase 2
-
Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.